Sofie and PerkinElmer to market preclinical hybrids, biopharmaceuticals

PerkinElmer announced an agreement with Sofie Biosciences this month to commercialize the latter's preclinical PET, 3D CT and X-ray systems.

In addition to these hybrid imaging systems, the Culver City, Calif., based company will be working directly with PerkinElmer to develop strategies for expanding Sofie’s biopharmaceutical development.

"Our relationship combines PerkinElmer's preclinical leadership with Sofie's PET expertise to bring new translational imaging solutions to the global research community," said Patrick Phelps, president and CEO of Sofie Biosciences, in a press release.

The partnership will be focusing on areas of research in pharmacology, oncology, immunology, cardiology and neurobiology. A new preclinical PET/CT system is in the wings.

"As a leading provider of imaging platforms for cellular, tissue and in vivo research, PerkinElmer is pleased to partner with Sofie, a leader in the field of PET imaging, to deliver these systems to the global preclinical research community," said PerkinElmer Life Sciences and Technology president Brian Kim. "In vivo preclinical imaging plays an integral role in translational research and drug discovery, facilitating a unique understanding of disease initiation, progression and therapeutic responses."

Trimed Popup
Trimed Popup